Skip to content
FORSIDEN
Log ind Opret konto
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Maj 2024

Genmab — Maj 2024

Planlagt Fastgjort Låst Flyttet Genmab
540 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • L Offline
    L Offline
    lahn1
    wrote on sidst redigeret af
    #518

    Effective in Lower CD38 Expression: The study shows that Hexabody-CD38 is effective even in cell lines with lower levels of CD38 expression, which is a common issue in DARA-resistant multiple myeloma (MM) patients.

    1 Reply Last reply
    0
    • L Offline
      L Offline
      lahn1
      wrote on sidst redigeret af
      #519

      No Inhibition by Preincubation with DARA: Preclinical studies indicate that preincubation with DARA does not inhibit Hexabody-CD38 from reaching its full capacity to induce CDC, suggesting that Hexabody-CD38 can still be effective even if DARA has been used previously.

      1 Reply Last reply
      0
      • L Offline
        L Offline
        lahn1
        wrote on sidst redigeret af
        #520

        In Vivo and Ex Vivo Efficacy: Hexabody-CD38 has demonstrated strong anti-tumor activity in patient-derived xenograft (PDX) models and primary MM cells, including those from DARA-refractory patients, indicating its potential effectiveness in a clinical setting.

        1 Reply Last reply
        0
        • L Offline
          L Offline
          lahn1
          wrote on sidst redigeret af
          #521

          Relief of Immune Suppression: Hexabody-CD38 strongly inhibits CD38 cyclase activity, which is hypothesized to relieve immune suppression in the tumor microenvironment, providing an additional therapeutic benefit.

          1 Reply Last reply
          0
          • L Offline
            L Offline
            lahn1
            wrote on sidst redigeret af
            #522

            In summary, the combination of enhanced CDC, robust multi-faceted mechanisms of action, effectiveness in lower CD38 expression levels, and promising preclinical results all suggest that Hexabody-CD38 should help patients who are resistant to Darzalex. The ongoing clinical trials will provide further validation of its safety and efficacy in this patient population.

            1 Reply Last reply
            0
            • L Offline
              L Offline
              lahn1
              wrote on sidst redigeret af
              #523

              Alle patienter på Dara progresserjo desværre så mener det er meget relevant on Hexabody-cd38 virker hvis ikke JnJ opter ind.

              1 Reply Last reply
              0
              • E Offline
                E Offline
                E_L
                wrote on sidst redigeret af
                #524

                can you also ask AI what the share price will be at the end of the year, given these conclusions? 😉

                1 Reply Last reply
                0
                • E Offline
                  E Offline
                  E_L
                  wrote on sidst redigeret af
                  #525

                  ASCO LBA out: Subcutaneous amivantamab vs intravenous amivantamab https://meetings.asco.org/abstracts-presentations/232405 . seems like a slam dunk.

                  1 Reply Last reply
                  0
                  • S Offline
                    S Offline
                    Sukkeralf
                    wrote on sidst redigeret af
                    #526

                    Do we know for sure if Genmab gets the same royalty for
                    an sc version of amivantamab?

                    1 Reply Last reply
                    0
                    • E Offline
                      E Offline
                      E_L
                      wrote on sidst redigeret af
                      #527

                      wtf I see Volume
                      704,391shares on Yahoo, is that correct

                      1 Reply Last reply
                      0
                      • E Offline
                        E Offline
                        E_L
                        wrote on sidst redigeret af
                        #528

                        no i am not sure about that, i think once there was a question on the Q&A on this if i am not mistaken after Dara and Genmab answered something like 'all other contracts are fine'? anyone remember?

                        1 Reply Last reply
                        0
                        • M Offline
                          M Offline
                          mobbyduck1
                          wrote on sidst redigeret af
                          #529

                          end of the q2 EL

                          1 Reply Last reply
                          0
                          • M Offline
                            M Offline
                            mobbyduck1
                            wrote on sidst redigeret af
                            #530

                            last day.crazy volume

                            1 Reply Last reply
                            0
                            • S Offline
                              S Offline
                              Sukkeralf
                              wrote on sidst redigeret af
                              #531

                              Yes - but do we believe that. Jan said the same about sc dara in the b
                              eginning

                              1 Reply Last reply
                              0
                              • E Offline
                                E Offline
                                E_L
                                wrote on sidst redigeret af
                                #532

                                no its only month end, not Q end yet

                                1 Reply Last reply
                                0
                                • E Offline
                                  E Offline
                                  E_L
                                  wrote on sidst redigeret af
                                  #533

                                  i don't know what to believe anymore... at least now they know how to do an arbitration correct this time around...

                                  1 Reply Last reply
                                  0
                                  • E Offline
                                    E Offline
                                    E_L
                                    wrote on sidst redigeret af
                                    #534

                                    talking about arbitration; we haven't seen volume like this in years; last time bigger was september 2020 when the arbitration started...

                                    1 Reply Last reply
                                    0
                                    • StockBullS Offline
                                      StockBullS Offline
                                      StockBull
                                      wrote on sidst redigeret af
                                      #535

                                      Jeg kan varmt anbefale, at enhver udtalelse fra nohope tages med et gran salt. Men det ved vi jo.

                                      1 Reply Last reply
                                      0
                                      • E Offline
                                        E Offline
                                        E_L
                                        wrote on sidst redigeret af
                                        #536

                                        ASCO24 Preview: A Look at Some of the Cancer Meeting’s Hottest Abstracts https://www.biospace.com/article/asco-2024-preview-a-look-at-some-of-the-cancer-meeting-s-hottest-abstracts

                                        1 Reply Last reply
                                        0
                                        • E Offline
                                          E Offline
                                          E_L
                                          wrote on sidst redigeret af
                                          #537

                                          'On June 3, researchers will be presenting Phase II data on Pfizer and Genmab’s Tivdak (tisotumab vedotin) in head and neck squamous cell carcinoma. Analysts from Leerink Partners were encouraged by the data, positing that they “could see antibody drug-conjugates (ADCs) eventually replace chemotherapy in [the] head and neck cancer treatment paradigm, particularly in the second line space,” according to a report.

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper